New Paper Alert
Paolo Tarantino: T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
Paolo Tarantino/LinkedIn

Paolo Tarantino: T-DXd Improves PFS in First-Line HER2-Mutant NSCLC

Paolo Tarantino, Visiting Professor at McGill University Health Centre, shared on X:

“First line T-DXd improved PFS over the platinum-pemetrexed-pembro triplet in HER2m NSCLC.”

Title: Enhertu Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

Paolo Tarantino: T-DXd Improves PFS in First-Line HER2-Mutant NSCLC

Read The Full Article.

cancer cancer care Cancer research DESTINY-Lung04 Enhertu HER2 HER2-mutant HER2m Lung cancer McGill University Health Centre NSCLC OncoDaily Oncology Paolo Tarantino PFS small cell lung cancer T-Dxd